Currently, there are three biomarkers used for GC diagnosis: human epidermal growth factor receptor 2 (HER2), microsatellite instability-high (MSI-H), and programmed death-ligand 1 (PD-L1) [101]. This evidence concerns the gene ERBB2 and gastric cancer.